3,233 Shares in Zimmer Biomet Holdings Inc (NYSE:ZBH) Purchased by Red Spruce Capital LLC

Red Spruce Capital LLC acquired a new position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,233 shares of the medical equipment provider’s stock, valued at approximately $484,000.

Other large investors have also recently made changes to their positions in the company. Tamarack Advisers LP raised its holdings in Zimmer Biomet by 77.8% during the 3rd quarter. Tamarack Advisers LP now owns 160,000 shares of the medical equipment provider’s stock worth $21,963,000 after purchasing an additional 70,000 shares during the last quarter. National Pension Service raised its holdings in Zimmer Biomet by 5.0% during the 3rd quarter. National Pension Service now owns 272,636 shares of the medical equipment provider’s stock worth $37,425,000 after purchasing an additional 12,901 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Zimmer Biomet by 312.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 656 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 497 shares during the last quarter. Lowe Brockenbrough & Co. Inc. raised its holdings in Zimmer Biomet by 13.5% during the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 6,325 shares of the medical equipment provider’s stock worth $868,000 after purchasing an additional 750 shares during the last quarter. Finally, Endurant Capital Management LP raised its holdings in Zimmer Biomet by 39.1% during the 3rd quarter. Endurant Capital Management LP now owns 152,496 shares of the medical equipment provider’s stock worth $20,933,000 after purchasing an additional 42,864 shares during the last quarter. 87.45% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Aure Bruneau sold 15,171 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $146.78, for a total transaction of $2,226,799.38. 0.72% of the stock is currently owned by corporate insiders.

Shares of ZBH stock opened at $148.15 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.17 and a quick ratio of 0.54. The stock has a market cap of $30.51 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 2.51 and a beta of 1.15. The stock has a 50-day moving average of $148.47 and a 200-day moving average of $138.21. Zimmer Biomet Holdings Inc has a one year low of $103.17 and a one year high of $151.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.02. Zimmer Biomet had a positive return on equity of 13.71% and a negative net margin of 1.14%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the prior year, the business posted $1.63 EPS. Zimmer Biomet’s revenue was up 3.0% on a year-over-year basis. As a group, research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.83 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, December 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.65%. Zimmer Biomet’s payout ratio is 12.57%.

Several brokerages have weighed in on ZBH. Raymond James raised Zimmer Biomet from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $160.00 to $170.00 in a report on Wednesday, December 4th. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $145.00 to $155.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Citigroup raised Zimmer Biomet from a “neutral” rating to a “buy” rating in a report on Thursday, January 2nd. Piper Jaffray Companies raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $170.00 in a report on Tuesday, January 7th. Finally, Canaccord Genuity raised Zimmer Biomet from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $137.00 to $167.00 in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $154.35.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: What is a Derivative?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.